Culture of patient-derived multicellular clusters in suspended hydrogel capsules for pre-clinical personalized drug screening
Open accessThe DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.
Abstract
A personalized medication regimen provides precise treatment for an individual and can be guided by pre-clinical drug screening. The economical and high-efficiency simulation of the liver tumor microenvironment (TME) in a drug-screening model has high value yet challenging to accomplish. Herein, we propose a simulation of the liver TME with suspended alginate-gelatin hydrogel capsules encapsulating patient-derived liver tumor multicellular clusters, and the culture of patient-derived tumor organoids(PDTOs) for personalized pre-clinical drug screening. The hydrogel capsule offers a 3D matrix environment with mechanical and biological properties similar to those of the liver in vivo. As a result, 18 of the 28 patient-derived multicellular clusters were successfully cultured as PDTOs. These PDTOs, along with hepatocyte growth factor (HGF) of non-cellular components, preserve stromal cells, including cancer-associated fibroblasts (CAFs) and vascular endothelial cells (VECs). They also maintain stable expression of molecular markers and tumor heterogeneity similar to those of the original liver tumors. Drugs, including cabazitaxel, oxaliplatin, and sorafenib, were tested in PDTOs. The sensitivity of PDTOs to these drugs differs between individuals. The sensitivity of one PDTO to oxaliplatin was validated using magnetic resonance imaging (MRI) and biochemical tests after oxaliplatin clinical treatment of the corresponding patient. Therefore, this approach is promising for economical, accurate, and high-throughput drug screening for personalized treatment.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Modeling Development and Disease with Organoids
Clevers, H. (2016) · Cell · doi:10.1016/j.cell.2016.05.082 · Cited by 3,196
Dijkstra, K. K., Cattaneo, C. M., Weeber, F., Chalabi, M., van de Haar, J., Fanchi, L. F., Slagter, M., van der Velden, D. L., Kaing, S., Kelderman, S., et al. (2018) · Cell · doi:10.1016/j.cell.2018.07.009 · Cited by 1,135
Microbiota triggers STING-type I IFN-dependent monocyte reprogramming of the tumor microenvironment
Lam, K. C., Araya, R. E., Huang, A., Chen, Q., Di Modica, M., Rodrigues, R. R., Lopès, A., Johnson, S. B., Schwarz, B., Bohrnsen, E., et al. (2021) · Cell · doi:10.1016/j.cell.2021.09.019 · Cited by 604
Organoid Models of Human Liver Cancers Derived from Tumor Needle Biopsies
Nuciforo, S., Fofana, I., Matter, M. S., Blumer, T., Calabrese, D., Boldanova, T., Piscuoglio, S., Wieland, S., Ringnalda, F., Schwank, G., et al. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.07.001 · Cited by 473 · cited 1×
“Among them, cabazitaxel and oxaliplatin are commonly used in clinical tumor chemotherapy, while sorafenib is commonly used in targeted therapy [38,43,44].”
BackgroundRecapitulating macro-scale tissue self-organization through organoid bioprinting
Brassard, J. A., Nikolaev, M., Hübscher, T., Hofer, M., & Lutolf, M. P. (2021) · Nature Materials · doi:10.1038/s41563-020-00803-5 · Cited by 469 · cited 1×
“In addition, there were alternative formation processes for hydrogels; PDTOs can also be produced with hydrogels through 3D bioprinting [50,51], microfluidics [52–54], or organ/tumor-on-a-chip [55–57].”
BackgroundShirure, V. S., Bi, Y., Curtis, M. B., Lezia, A., Goedegebuure, M. M., Goedegebuure, S. P., Aft, R., Fields, R. C., & George, S. C. (2018) · Lab on a Chip · doi:10.1039/c8lc00596f · Cited by 316
Organ-on-a-Chip for Cancer and Immune Organs Modeling
Sun, W., Luo, Z., Lee, J., Kim, H., Lee, K., Tebon, P., Feng, Y., Dokmeci, M. R., Sengupta, S., & Khademhosseini, A. (2019) · Advanced Healthcare Materials · doi:10.1002/adhm.201801363 · Cited by 221
An organoid-based organ-repurposing approach to treat short bowel syndrome
Sugimoto, S., Kobayashi, E., Fujii, M., Ohta, Y., Arai, K., Matano, M., Ishikawa, K., Miyamoto, K., Toshimitsu, K., Takahashi, S., et al. (2021) · Nature · doi:10.1038/s41586-021-03247-2 · Cited by 175
Hepatic organoids for microfluidic drug screening
Au, S. H., Chamberlain, M. D., Mahesh, S., Sefton, M. V., & Wheeler, A. R. (2014) · Lab on a Chip · doi:10.1039/c4lc00531g · Cited by 162
Three-dimensional bio-printing of primary human hepatocellular carcinoma for personalized medicine
Xie, F., Sun, L., Pang, Y., Xu, G., Jin, B., Xu, H., Lu, X., Xu, Y., Du, S., Wang, Y., et al. (2021) · Biomaterials · doi:10.1016/j.biomaterials.2020.120416 · Cited by 147 · cited 1×
“In addition, there were alternative formation processes for hydrogels; PDTOs can also be produced with hydrogels through 3D bioprinting [50,51], microfluidics [52–54], or organ/tumor-on-a-chip [55–57].”
Background
Cited by
Organoid co‐culture models of the tumor microenvironment promote precision medicine
Gu, Z., Wu, Q., Shang, B., Zhang, K., & Zhang, W. (2024) · Cancer Innovation · doi:10.1002/cai2.101 · Cited by 47
Emerging Functional Porous Scaffolds for Liver Tissue Engineering
Wang, J., Huang, D., Chen, D., Ren, H., & Zhao, Y. (2025) · Advanced Healthcare Materials · doi:10.1002/adhm.202403741 · Cited by 15
Li, Q., Nichols, C., Welner, R. S., Chen, J. Y., Ku, W.-S., & Yue, Z. (2026) · Briefings in Bioinformatics · doi:10.1093/bib/bbag244
Metadata
- Authors
- Dong, H., Li, Z., Bian, S., Song, G., Song, W., Zhang, M., Xie, H., Zheng, S., Yang, X., Li, T., & Song, P.
- Venue
- Bioactive Materials
- Publisher
- Elsevier BV
- Published
- 2022-12
- Volume
- 18
- Pages
- 164-177
- ISSN
- 2097-1192 (ISSN-L)
- 2452-199X
- OpenAlex
- W4220993052
- Cited by
- 38
- References
- 16
- FWCI
- 2.43
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Culture of patient-derived multicellular clusters in suspended hydrogel capsules for pre-clinical personalized drug screening. https://app.cochat.ai/papers/10.1016/j.bioactmat.2022.03.020
- The paper
- Dong, H., Li, Z., Bian, S., Song, G., Song, W., Zhang, M., Xie, H., Zheng, S., Yang, X., Li, T., & Song, P. (2022). Culture of patient-derived multicellular clusters in suspended hydrogel capsules for pre-clinical personalized drug screening. Bioactive Materials. https://doi.org/10.1016/j.bioactmat.2022.03.020
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.